drug · antibody

PRALUENT

updated 5mo ago

by $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 2

Antibody drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 6 investigational indications.

targets

Proprotein convertase subtilisin/kexin type 9

all catalysts(0)

nothing on the calendar yet

Trials studying PRALUENT

—Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practicecompletedn=996
phase2A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemiarecruitingn=420
—Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)active not recruitingn=2,214
phase2PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lungactive not recruitingn=60
phase2TOP 2301: Neoadjuvant Chemo for NSCLCsuspendedn=126
—Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russiarecruitingn=2,382
phase1Alirocumab in Patients with Sepsiscompletedn=50
—Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patientsrecruitingn=10,000

News(5)

Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.
biospace · 2mo ago
Gene editing developer Scribe plots an IPO
The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go public in 2026.
biopharma_dive · 3mo ago
Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
Lilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.
biopharma_dive · 5mo ago
STAT+: Pharmalittle: We’re reading about a Trump deal with Regeneron, reclassifying medical marijuana, and more
President Trump heralded a drug-pricing agreement with Regeneron, closing the last of 17 deals sought by the White House
stat · 5mo ago
STAT+: Trump celebrates closing first round of drug pricing deals, promises more ahead
A deal with Regeneron was the last of 17 initially sought by the White House.
stat · 5mo ago

brand

PRALUENT

trade names

Praluent

generic

ALIROCUMAB

MOA

12.1 Mechanism of Action Alirocumab is a human monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein (LDL) receptors (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to LDLR, alirocumab increases the number of LDLRs available to clear LDL, thereby lowering LDL-C levels.

indication

1 INDICATIONS AND USAGE PRALUENT ® is indicated: To reduce the risk of major adverse cardiovascular (CV) events (coronary heart disease death, myocardial infarction, stroke, or unstable angina requiring hospitalization) in adults at increased risk for these events . As an adjunct to diet and exercise to reduce low- density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia. adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). adults with homozygous familial hypercholesterolemia (HoFH). PRALUENT is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor indicated: To reduce the risk of major adverse cardiovascular (CV) events (coronary heart disease death, myocardial infarction, stroke, or unstable angina requiring hospitalization) in adults at increased risk for these events. ( 1 ) As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in : adults with hypercholesterolemia ( 1 ) adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). ( 1 ) adults with homozygous familial hypercholesterolemia (HoFH). ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 43m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · antibody

save

PRALUENT

updated 5mo ago

by $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 2

Antibody drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 6 investigational indications.

targets

Proprotein convertase subtilisin/kexin type 9

all catalysts(0)

nothing on the calendar yet

Trials studying PRALUENT

—Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practicecompletedn=996
phase2A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemiarecruitingn=420
—Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)active not recruitingn=2,214
phase2PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lungactive not recruitingn=60
phase2TOP 2301: Neoadjuvant Chemo for NSCLCsuspendedn=126
—Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russiarecruitingn=2,382
phase1Alirocumab in Patients with Sepsiscompletedn=50
—Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patientsrecruitingn=10,000

News(5)

Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.
biospace · 2mo ago
Gene editing developer Scribe plots an IPO
The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go public in 2026.
biopharma_dive · 3mo ago
Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
Lilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.
biopharma_dive · 5mo ago
STAT+: Pharmalittle: We’re reading about a Trump deal with Regeneron, reclassifying medical marijuana, and more
President Trump heralded a drug-pricing agreement with Regeneron, closing the last of 17 deals sought by the White House
stat · 5mo ago
STAT+: Trump celebrates closing first round of drug pricing deals, promises more ahead
A deal with Regeneron was the last of 17 initially sought by the White House.
stat · 5mo ago

brand

PRALUENT

trade names

Praluent

generic

ALIROCUMAB

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 43m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

PRALUENT

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying PRALUENT

News(5)

Report a data issue

comments(0)

PRALUENT

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying PRALUENT

News(5)

Report a data issue

comments(0)